Form 4: Neuraxis CMO Granted 75,000 Restricted Stock Units

Neuraxis's CMO and SVP of Science & Technology, Adrian Miranda, was granted a total of 75,000 Restricted Stock Units under various incentive plans.

Summary

• Adrian Miranda, the Chief Medical Officer (CMO) and Senior Vice President (SVP) of Science & Technology at Neuraxis, INC (NRXS), was granted a total of 75,000 Restricted Stock Units (RSUs).
• The grants occurred on two separate dates: January 3, 2025, and March 4, 2025.
• On March 4, 2025, 10,000 RSUs were granted as a bonus under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, with an underlying common stock price of $2.18 per share.
• Also on March 4, 2025, an additional 30,000 RSUs were granted under the Long-Term Incentive Plan, also at an underlying common stock price of $2.18 per share.
• On January 3, 2025, 35,000 RSUs were granted under the Long-Term Incentive Plan, with an underlying common stock price of $2.42 per share.
• All 75,000 RSUs are scheduled to vest in full at the end of 36 months from their respective grant dates.
• Following these transactions, Adrian Miranda directly beneficially owns 75,000 derivative securities (RSUs).

Sentiment

Score: 5

Explanation: This Form 4 filing reports a routine executive compensation grant and does not contain information that would significantly alter the company's fundamental outlook or financial performance, thus maintaining a neutral sentiment.

Positives

• The grant of 75,000 Restricted Stock Units (RSUs) to a key executive, Adrian Miranda, aligns management's long-term interests with those of shareholders.
• The use of established incentive plans (2022 Omnibus Securities and Incentive Plan and Long-Term Incentive Plan) demonstrates a structured approach to executive compensation and retention.

Negatives

• No immediate cash benefit for the executive, as the RSUs are subject to a 36-month vesting period.
• The ultimate value of the compensation is tied to the future performance of Neuraxis's stock price, introducing market risk for the executive.

Risks

• Stock Price Volatility: The ultimate value of the RSUs to the reporting person is dependent on the future market price of Neuraxis common stock, which can fluctuate.
• Forfeiture Risk: The RSUs will only vest after 36 months, meaning the reporting person risks forfeiture of the unvested units if employment terminates before the vesting period is complete.
• Potential Dilution: The eventual conversion of these RSUs into common stock could lead to minor dilution for existing shareholders.

Future Outlook

The granted Restricted Stock Units (RSUs) are scheduled to vest in full at the end of 36 months from their respective grant dates, indicating a long-term retention and incentive strategy for the executive.

Industry Context

The grant of Restricted Stock Units (RSUs) to key executives is a common practice in the biotechnology and pharmaceutical industries, as well as other sectors, to incentivize long-term performance and align management interests with shareholder value. This type of compensation is a standard component of executive remuneration packages.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) with a multi-year vesting schedule (36 months) is a standard practice for executive compensation across various industries, including biotech.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals frequently utilize similar long-term incentive structures to retain talent and motivate performance.
• The specific number of units granted (75,000) and the underlying value ($2.18 $2.42 per share) would typically be benchmarked against peer companies of similar market capitalization and stage of development, considering the executive's role and contribution. Without specific peer compensation data, a direct quantitative comparison is not feasible from this filing alone.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU grants aim to align the interests of a key executive with shareholders, potentially leading to better long-term performance. However, future vesting and conversion to common stock will result in minor dilution.
• Employees: While this filing specifically pertains to an executive, the existence of incentive plans suggests a broader framework for employee motivation, potentially impacting morale and retention across the company.

Next Steps

• The granted RSUs will vest in full at the end of 36 months from their respective grant dates, at which point they will convert into common stock.

Key Dates

Keywords

Neuraxis, NRXS, RSU, Restricted Stock Units, Executive Compensation, Adrian Miranda, Form 4, Insider Transaction, Long-Term Incentive Plan